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Background
Duchenne muscular dystrophy (DMD) is the most com-
mon inherited form of muscular dystrophy, which
results in skeletal muscle weakness by age 6. In its later
stages DMD leads to dilated cardiomyopathy and heart
failure with high level of mortality. At present there are
no effective treatments for most of the cardiac pathology
in DMD patients.
Results
Recently we showed that sildenafil could reverse much of
the cardiac dysfunction in the mdx mouse model of DMD.
Treatments with sildenafil (in the drinking water) resulted
in significant improvements in cardiac function, analyzed
by the myocardial performance index (MPI) and Ea/Aa
ratios [1]. Similar improvements in cardiac functions were
also observed when sildenafil was administered daily for
one week by oral gavage (60 mg/kg). However, daily
administration of tadalafil by oral gavage (4 and 20 mg/kg)
did not produce any improvement in the myocardial per-
formance index.
In order to provide a reliable indicator for efficacy of
dosing of different PDE5 inhibitors we examined the levels
of PDE5 phosphorylation in tissues known to express
PDE5, e.g. lung and blood vessels, as a biological indicator
of cGMP induced PKG activation in vivo. We found that
both tadalafil and sildenafil caused time-dependent equiva-
lent phosphorylation of PDE5 in these tissues. Similar
PDE5 phosphorylation patterns were observed in cardiac
tissue extracts. Since no PDE5 expression has been
detected in adult mouse cardiac myocytes, we consider
phospho-PDE5 in the cardiac samples to be from cardiac
blood vessels, myofibroblasts and even platelets from resi-
dual blood.
Differential effects of PDE5 inhibitors on cardiac dys-
functions in MDX mice could point to PDE1C, which can
be partially inhibited by sildenafil, but not by tadalafil.
PDE1C is the calcium/calmodulin cGMP/cAMP PDE,
most highly expressed in mouse cardiac myocytes. How-
ever, the functions of PDE1C in myocytes have not been
determined.
We used specific PDE1 inhibitors (Intra-Cellular
Therapies, NY) and found that these inhibitors could
substantially stimulate cGMP-induced phosphorylation
of phospholamban by C-type natriuretic peptide (CNP).
Moreover, in cardiac myocytes, isolated from PDE1C
KO mice, CNP-induced phosphorylation of phospho-
lamban was substantially higher, and no additional
increase of its phosphorylation was detected with PDE1
specific inhibitors.
However, we did not detect any induction of phosho-
lamban phosphorylation when sildenafil was applied to
mouse cardiac myocytes even at high concentrations; and
tadalafil did not have any effects as well. Although the pat-
tern of PDE5 phosphorylation after sildenafil and tadalafil
application by oral gavage corresponded to the differences
in the pharmacokinetics of these drugs, they produced dif-
ferential changes in ERK, VASP and GSKb phosphoryla-
tion in lung and heart, often in different directions.
Conclusion
These data suggest that the sildenafil and tadalafil differen-
tial effects could be the result of indirect effects of these
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drugs on other cell types, subsequently affecting cardiac
functions.
However, PDE1 specific inhibitors appear to be new
potential agents for direct regulation of phospholamban
phosphorylation and calcium homeostasis in the heart.
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